Format
Sort by
Items per page

Send to

Choose Destination

Best matches for off-label use AND prescribing behavior:

Awareness, knowledge and views of off-label prescribing in children: a systematic review. Balan S et al. Br J Clin Pharmacol. (2015)

Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety. Laprevote V et al. Curr Pharm Des. (2015)

[Guide to perfect prescribing in Switzerland]. Arnet I et al. Ther Umsch. (2014)

Search results

Items: 1 to 20 of 74

1.

Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.

Anand S, Tong H, Besag FMC, Chan EW, Cortese S, Wong ICK.

Paediatr Drugs. 2017 Jun;19(3):235-250. doi: 10.1007/s40272-017-0224-6. Review.

PMID:
28391425
2.

Prescription Drug Use and Polypharmacy Among Medicaid-Enrolled Adults with Autism: A Retrospective Cross-Sectional Analysis.

Vohra R, Madhavan S, Sambamoorthi U, StPeter C, Poe S, Dwibedi N, Ajmera M.

Drugs Real World Outcomes. 2016 Dec;3(4):409-425.

3.

Challenges to the validity of using medicine labels to categorize clinical behavior: An empirical and normative critique of "off-label" prescribing.

Ghinea N, Kerridge I, Little M, Lipworth W.

J Eval Clin Pract. 2017 Jun;23(3):574-581. doi: 10.1111/jep.12673. Epub 2016 Nov 14.

PMID:
27859988
4.

Informed Family Member Involvement to Improve the Quality of Dementia Care in Nursing Homes.

Tjia J, Lemay CA, Bonner A, Compher C, Paice K, Field T, Mazor K, Hunnicutt JN, Lapane KL, Gurwitz J.

J Am Geriatr Soc. 2017 Jan;65(1):59-65. doi: 10.1111/jgs.14299. Epub 2016 Aug 22.

PMID:
27550398
5.

Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.

Mullins TL, Zimet G, Lally M, Kahn JA.

AIDS Patient Care STDS. 2016 Jul;30(7):339-48. doi: 10.1089/apc.2016.0048.

6.

Androgens and Female Sexual Function and Dysfunction--Findings From the Fourth International Consultation of Sexual Medicine.

Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N.

J Sex Med. 2016 Feb;13(2):168-78. doi: 10.1016/j.jsxm.2015.12.033. Review.

PMID:
26953831
7.

Utilisation of prescription and over-the-counter triptans: a cross-sectional study in Stockholm, Sweden.

Frisk P, Sporrong SK, Ljunggren G, Wettermark B, von Euler M.

Eur J Clin Pharmacol. 2016 Jun;72(6):747-54. doi: 10.1007/s00228-016-2028-y. Epub 2016 Feb 27.

PMID:
26922586
8.
9.

Use of Antipsychotic Medications for Nonpsychotic Children: Risks and Implications for Mental Health Services.

Daviss WB, Barnett E, Neubacher K, Drake RE.

Psychiatr Serv. 2016 Mar;67(3):339-41. doi: 10.1176/appi.ps.201500272. Epub 2016 Jan 4.

PMID:
26725298
10.

Paradoxes of evidence in Russian addiction medicine.

Mendelevich VD, Zalmunin KY.

Int J Risk Saf Med. 2015;27 Suppl 1:S102-3. doi: 10.3233/JRS-150708.

PMID:
26639682
11.

Adherence to evidence-based treatment guidelines for bipolar depression in an inpatient setting.

Freeland KN, Cogdill BR, Ross CA, Sullivan CO, Drayton SJ, VandenBerg AM, Short EB, Garrison KL.

Am J Health Syst Pharm. 2015 Dec 1;72(23 Suppl 3):S156-61. doi: 10.2146/sp150023.

PMID:
26582302
12.

Awareness, knowledge and views of off-label prescribing in children: a systematic review.

Balan S, Hassali MA, Mak VS.

Br J Clin Pharmacol. 2015 Dec;80(6):1269-80. doi: 10.1111/bcp.12750. Epub 2015 Nov 6. Review.

13.

Venlafaxine for neuropathic pain in adults.

Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC.

Cochrane Database Syst Rev. 2015 Aug 23;(8):CD011091. doi: 10.1002/14651858.CD011091.pub2. Review.

PMID:
26298465
14.

High doses of Baclofen as suicide attempt in patients with alcohol use disorders - A serious concern.

Holla B, Gowda GS, Prabhu L, Baby S, Viswanath B, Chand P, Murthy P.

Asian J Psychiatr. 2015 Oct;17:99-100. doi: 10.1016/j.ajp.2015.06.015. Epub 2015 Jul 3.

PMID:
26264491
15.

Borderline Personality Disorder and Oxytocin: Review of Clinical Trials and Future Directions.

Amad A, Thomas P, Perez-Rodriguez MM.

Curr Pharm Des. 2015;21(23):3311-6. Review.

PMID:
26088114
16.

Is There a Place for Off-Label Pharmacotherapy in Cannabis Use Disorder? A Review on Efficacy and Safety.

Laprevote V, Schwan R, Schwitzer T, Rolland B, Thome J.

Curr Pharm Des. 2015;21(23):3298-305. Review.

PMID:
26088109
17.

Pharmacotherapy for borderline patients: business as usual or by default?

Ingenhoven T.

J Clin Psychiatry. 2015 Apr;76(4):e522-3. doi: 10.4088/JCP.14com09522.

18.

The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services.

Paton C, Crawford MJ, Bhatti SF, Patel MX, Barnes TR.

J Clin Psychiatry. 2015 Apr;76(4):e512-8. doi: 10.4088/JCP.14m09228.

19.

Are risk evaluation and mitigation strategies associated with less off-label use of medications? The case of immune thrombocytopenia.

Sarpatwari A, Franklin JM, Avorn J, Seeger JD, Landon JE, Kesselheim AS.

Clin Pharmacol Ther. 2015 Feb;97(2):186-93. doi: 10.1002/cpt.17. Epub 2014 Dec 20.

PMID:
25670524
20.

A plea for rational mitigation of poor outcomes in the 'off-label use' of medications for the management of pain.

Khursheed F, Ioffe J, Gould HJ 3rd.

J Neurol Sci. 2015 Feb 15;349(1-2):72-6. doi: 10.1016/j.jns.2014.12.028. Epub 2014 Dec 27.

PMID:
25579412

Supplemental Content

Loading ...
Support Center